育龄期阿片使用障碍女性丙型肝炎诊疗中的种族与民族差异
基于美国TriNetX电子健康记录网络2014至2022年育龄期(15-44岁)阿片使用障碍女性队列,44.6%接受HCV抗体检测,亚裔和非裔美国人检测概率低于白人,感染者中仅9.1%接受直接抗病毒药物治疗,西班牙裔/拉丁裔治疗概率高于非西班牙裔/拉丁裔。
要点
- 育龄期阿片使用障碍女性中仅44.6%接受HCV抗体检测,感染者中仅9.1%接受直接抗病毒药物治疗。
- 亚裔和非裔美国人HCV抗体检测概率低于白人(风险比分别为0.77和0.76)。
- 西班牙裔/拉丁裔感染者治疗概率高于非西班牙裔/拉丁裔(风险比1.63)。
核心结论
- 少数育龄期阿片使用障碍女性接受HCV检测或治疗,HCV检测中的种族和民族差异进一步加剧少数族群围产期传播和疾病进展风险,需要干预措施改善HCV筛查和治疗总体覆盖率及公平性。
研究设计与样本
- 分析TriNetX研究网络(美国电子健康记录网络)中诊断为阿片使用障碍的育龄期女性(15-44岁)队列数据,使用对数二项模型评估HCV关怀级联各阶段(HCV抗体检测、HCV感染[HCV RNA检测阳性]、 linkage to care、HCV治疗)的种族和民族差异。
主要发现
- 2014年至2022年,队列中44.6%接受HCV抗体检测。
- 亚裔和非裔美国人HCV抗体检测概率低于白人(风险比0.77[95%CI 0.62-0.96]和0.76[95%CI 0.63-0.92])。
- HCV感染者中仅9.1%接受直接抗病毒药物治疗。
- 西班牙裔/拉丁裔感染者治疗概率高于非西班牙裔/拉丁裔(风险比1.63[95%CI 1.01-2.61])。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the United States, hepatitis C virus (HCV) diagnoses among reproductive-aged women are increasing amidst the ongoing opioid and drug overdose epidemic. While previous studies document racial and ethnic disparities in HCV testing and treatment in largely male populations, to our knowledge no national studies analyze these outcomes in reproductive-aged women with opioid use disorder (OUD). METHODS: We analyzed data from a cohort of reproductive-aged women (aged 15-44 years) with diagnosed OUD captured in the TriNetX Research Network, a network of electronic health records from across the United States. Using a log-binomial model, we assessed differences in achieving HCV cascade of care stages (HCV antibody testing, HCV infection [positive HCV RNA test result], linkage to care, and HCV treatment) by race and ethnicity. RESULTS: From 2014 to 2022, 44.6% of the cohort were tested for HCV antibody. Asian and black/African American individuals had a lower probability of having an HCV antibody test than white individuals (risk ratio, 0.77 [95% confidence interval, .62-.96] and 0.76 [.63-.92], respectively). Among those with HCV infection, only 9.1% were treated with direct-acting antivirals. Hispanic/Latinx individuals had a higher probability of treatment than non-Hispanic/Latinx individuals (risk ratio, 1.63 [95% confidence interval, 1.01-2.61]). CONCLUSIONS: Few reproductive-aged women with OUD are tested or treated for HCV. Disparities by race and ethnicity in HCV testing further exacerbate the risk of perinatal transmission and disease progression among minoritized communities. Interventions are needed to improve overall rates of and equity in HCV screening and treatment for reproductive-aged women.
引用
- Biondi BE, Munroe S, Lavarin C, et al. Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder. Clin Infect Dis. 2024. PMID: 39356149. doi:10.1093/cid/ciae426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。